Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation

Objective The efficacy and safety of concomitant use of antithrombin (AT) with recombinant human soluble thrombomodulin (rTM) for acute cholangitis-induced disseminated intravascular coagulation (AC-induced DIC) remains unclear. This study was conducted to investigate the efficacy of AT combined with rTM as anticoagulant therapy for AC-induced DIC. Methods One hundred patients with AC-induced DIC received anticoagulant therapy using rTM from April 2010 to December 2017. Of the 83 patients treated with rTM immediately after the diagnosis of DIC, excluding those who had not undergone biliary drainage or who had malignancies or a serum AT III level >70%, 56 patients were studied. Outcomes and adverse events (AEs) were retrospectively compared between the 16 patients treated with rTM alone (rTM group) and the 40 patients treated with rTM and AT (rTM+AT group). Results Patients' background characteristics did not differ markedly, except for a significantly higher serum D-dimer level in the rTM group than in the rTM+AT group (p=0.038). The DIC resolution rates on day 9 were 100% and 95.1% in the rTM and rTM+AT groups, respectively (p=0.909). The mean DIC scores were significantly lower in the rTM group than in the rTM+AT group on days 3 (p=0.012), 5 (p<0.001), 7 (p=0.033), and 9 (p=0.007). The incidence of AEs was 6.3% and 10.0% (p=0.941), and the in-hospital mortality rates was 0% and 5.0% (p=0.909) in the rTM and rTM+AT groups, respectively. Conclusion The concomitant use of AT with anticoagulant therapy using rTM for AC-induced DIC may not help improve the treatment outcome.

[1]  D. Gouma,et al.  Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis , 2018, Journal of hepato-biliary-pancreatic sciences.

[2]  D. Saitoh,et al.  Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation , 2017, Annals of Intensive Care.

[3]  Tsuyoshi Nakashima,et al.  Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011–2013 , 2016, Journal of Intensive Care.

[4]  T. Hayakawa,et al.  Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial , 2015, International Journal of Clinical Oncology.

[5]  Sumio Watanabe,et al.  Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field. , 2015, Biomedical reports.

[6]  H. Yuhara,et al.  Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta‐analysis , 2015, Journal of thrombosis and haemostasis : JTH.

[7]  F. Itoh,et al.  Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation. , 2015, World journal of gastroenterology.

[8]  D. Saitoh,et al.  Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey , 2014, Critical Care.

[9]  G. Bernard,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation* , 2013, Critical care medicine.

[10]  F. Itoh,et al.  Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis , 2013, Gut and liver.

[11]  D. Gouma,et al.  TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos) , 2013, Journal of hepato-biliary-pancreatic sciences.

[12]  I. Maruyama,et al.  THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION: SUBANALYSIS FROM THE PHASE 3 TRIAL , 2011, Shock.

[13]  Yasuhiro Ohtomo,et al.  A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria* , 2006, Critical care medicine.

[14]  S. Opal,et al.  Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation , 2006, Journal of thrombosis and haemostasis : JTH.

[15]  D. Inthorn,et al.  Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis* , 2004, Critical care medicine.

[16]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[17]  S. Yamamoto,et al.  Effects of Recombinant Human Soluble Thrombomodulin (rhs-TM) on a Rat Model of Disseminated Intravascular Coagulation with Decreased Levels of Plasma Antithrombin III , 1994, Thrombosis and Haemostasis.

[18]  S. Madoiwa,et al.  Expert consensus for the treatment of disseminated intravascular coagulation in Japan. , 2010, Thrombosis research.

[19]  S. Opal,et al.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.